Karma Biotechnologies is solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform.
Karma Biotechnologies has raised $31K in total funding. The most recent round was Seed. The last funding was announced in May 2023.
Karma Biotechnologies's investors include Gaingels, Khosla Ventures, Presight Capital, SOSV, Calm Ventures.
Karma Biotechnologies is headquartered in Torrance, United States.
Karma Biotechnologies is solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform.
Karma Biotechnologies is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Karma Biotechnologies — Funding & Investors." VCBacked, May 31, 2023, https://www.vcbacked.co/company/karma-biotechnologies. Accessed August 14, 2026.
VCBacked. (2023). Karma Biotechnologies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/karma-biotechnologies
{{cite web |title=Karma Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/karma-biotechnologies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated